10-K: Nu-Med Plus, Inc. Reports Annual Results for Fiscal Year 2023, Cites Going Concern Uncertainty

Nu-Med Plus, Inc. reports its 2023 annual results, highlighting ongoing product development challenges and a significant net loss, while also expressing substantial doubt about the company's ability to continue as a going concern.

Summary

• Nu-Med Plus, Inc., a medical device company focused on nitric oxide delivery systems, released its annual report for the fiscal year ended December 31, 2023.
• The company reported no revenue for the year and a net loss of $125,526, compared to a net loss of $130,167 in 2022.
• Operating expenses decreased to $120,526 in 2023 from $182,167 in 2022, primarily due to a reduction in consulting expenses.
• The company's total assets were $13,456, with current liabilities of $160,207, indicating a significant working capital deficit.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Product development has been suspended due to a lack of capital, and the company is seeking additional funding or a merger partner.
• The company has two approved patents and one pending patent related to its nitric oxide delivery systems.
• Management anticipates needing $1,250,000 to continue operations for the next year, but currently does not have the funds.
• The company is classified as both a Smaller Reporting Company and an Emerging Growth Company, allowing for reduced disclosure obligations.

Sentiment

Score: 2

Explanation: The document paints a very negative picture of the company's financial health and future prospects. The going concern warning, lack of revenue, and suspended product development indicate a high risk of failure.

Positives

• The company has developed initial prototypes for several nitric oxide delivery systems.
• The company has two approved patents and one pending patent, indicating some intellectual property value.
• Operating expenses were reduced in 2023 compared to 2022.
• The company is actively seeking additional funding or a merger partner to continue operations.

Negatives

• The company reported a significant net loss of $125,526 for 2023.
• The company has a substantial working capital deficit with total liabilities exceeding total assets.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Product development has been suspended due to a lack of capital.
• The company has no current revenue and is dependent on external funding.
• The company has material weaknesses in internal controls over financial reporting.
• The company relies on a small group of investors for funding, creating a concentration risk.

Risks

• The company's ability to continue as a going concern is highly uncertain due to recurring losses and negative cash flows.
• The company is dependent on raising additional capital, which may dilute current investors.
• The medical device industry is highly competitive, and the company faces competition from larger, better-funded companies.
• The company's success depends on the ability of management to develop and commercialize medical devices, which is not guaranteed.
• The company is subject to extensive regulations, including FDA approval, which can be a lengthy and expensive process.
• The company may be subject to product liability claims if its products cause harm.
• The company has material weaknesses in internal controls over financial reporting, which could lead to inaccuracies in financial statements.
• The company's reliance on a small group of investors creates a concentration risk.

Future Outlook

The company's future is uncertain, with management seeking additional funding or a merger partner to continue operations and product development. The company anticipates needing $1,250,000 to continue operations for the next year.

Management Comments

• Management believes that with the further refinement of our formulation, we can make and filter medical grade nitric oxide gas with minimal amounts of nitrogen dioxide.
• Management anticipates that selling our units earlier into the market as laboratory equipment or to international groups will pave the way for sales of our medical delivery devices.
• Management believes, with the costs to develop new technology and receive FDA regulatory approval for those devices, it is important to divide the capital needs into phases to be able to track development progress and anticipate capital needs better.

Industry Context

The company operates in the competitive medical device industry, specifically targeting the nitric oxide delivery market. The company faces competition from larger, well-established companies with greater resources. The market for nitric oxide therapies is expanding, but regulatory approvals are required for new uses and devices.

Comparison to Industry Standards

• Mallinckrodt Inc. is a major competitor with the only FDA approved nitric oxide delivery system (INOMAX) for newborns, highlighting the regulatory hurdles and market dominance challenges for Nu-Med.
• GeNO LLC is another competitor with a patented system for nitric oxide generation and delivery, indicating the technological competition in the space.
• Beyond Air (formerly AIT Therapeutics) is also developing nitric oxide delivery technology, showing the ongoing innovation and competition in the market.
• Unlike these established players, Nu-Med is a smaller company with limited resources, making it difficult to compete directly on a large scale.
• The company's focus on niche products and cost-effective delivery methods is a strategy to differentiate itself from larger competitors.

Related Party Transactions

• The Chief Financial Officer provided $11,740 to the company for operating expenses during the year, bringing the total funds he has provided to $45,640.
• A director of the company provided $478 for operating expenses during 2023.
• The total payable to officers and directors at December 31, 2023 is $46,118.
• Certain officers and directors of the Company forgave $164,500 in accrued expenses which had been due them for services in December 2022.
• The company issued 2,200,000 shares of restricted common stock to its officers and directors in 2023.
• The company issued 2,000,000 shares of restricted common stock to its President/Chief Executive Officer in 2022.

Stakeholder Impact

• Shareholders face a high risk of losing their investment due to the company's financial instability and going concern uncertainty.
• Employees are at risk of job loss if the company is unable to secure additional funding or a merger partner.
• Customers are not currently impacted as the company has no commercial products, but potential future customers may be affected if the company fails.
• Suppliers and creditors face the risk of non-payment if the company is unable to continue operations.

Next Steps

• The company will continue to seek additional funding or a merger partner.
• The company will continue to work on patent applications.
• The company will evaluate methods of improving internal control over financial reporting.

Key Dates

Keywords

Nitric Oxide, Medical Device, FDA Approval, Product Development, Capital Raise, Going Concern, Financial Reporting, Internal Controls, Patents, Healthcare